Abstract

P 005

Cost-effectiveness analysis of fixed combination therapies Ganfort, DuoTrav and Xalacom in European countries

Hommer A. B.¹, Wickstrøm J.², Friis M. M.², Poulsen P. B.²,Walt J.³, Buchholz P.^4
1Krankenanstalt Sanatorium, Vienna, Austria; ²MUUSMANN Research & Consulting, Kolding, Denmark; ³Allergan, Irvine, CA, USA; ⁴Allergan R&D Europe, Ettlingen, Germany

Objective: Fixed-combination drugs Ganfort (bimatoprost 0.03%/timolol 0.5%), Xalacom (latanoprost 0.005%/timolol 0.5% and DuoTrav (travoprost 0.004%/timolol 0.5%) are approved for treatment of patients with glaucoma or ocular hypertension. This study was designed to analyze the cost-effectiveness of each therapy in Denmark, Finland, France, Italy, Norway, Spain, Sweden and the United Kingdom.
Methods: In the absence of head-to-head clinical studies published studies with 3-month data for each of the drugs were indirectly evaluated for a cost-effectiveness analysis: 541 patients treated with Ganfort, 982 with DuoTrav and 517 with Xalacom. Cost evaluations included both medication costs and ophthalmologist visit costs. Drug costs were market prices, inclusive of VAT; visit costs used official tariffs. Main outcomes were cost-effectiveness ratios (representing the cost per percentage reduction in IOP) for each fixed-combination drug.
Results: Ganfort was the least costly of the three fixed-combination drugs, with a saving per percentage reduction in IOP ranging from €0.12 to €0.58 when compared with DuoTrav and €0.03 to €0.64 when compared to Xalacom.
Conclusions: Ganfort is more cost effective than DuoTrav and Xalacom in the countries studied, when applying the cost per percentage reduction in IOP.

Copyright: Porstmann Kongresse GmbH. All rights reserved. Impressum, Disclaimer.